Detalhe da pesquisa
1.
Outcomes for pembrolizumab stratified by pemetrexed maintenance post pembrolizumab-platinum-pemetrexed induction in metastatic non-small-cell lung cancer.
Immunotherapy
; 16(7): 453-464, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38487917
2.
Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting.
Front Oncol
; 14: 1298603, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38525422
3.
Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb).
Ther Adv Med Oncol
; 15: 17588359231182386, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37360769
4.
Real-world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy.
Cancer Med
; 12(22): 20783-20797, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37962239
5.
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
Clin Cancer Res
; 28(5): 903-914, 2022 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34862248
6.
Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
Clin Cancer Res
; 25(7): 2088-2095, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30617139
7.
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
NPJ Breast Cancer
; 5: 36, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31667338
8.
Correction: Efficacy and Safety of the Biosimilar ABP 215 Compared with Bevacizumab in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer (MAPLE): A Randomized, Double-blind, Phase III Study.
Clin Cancer Res
; 25(10): 3193, 2019 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31092617
9.
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer.
J Clin Oncol
; 31(32): 4105-14, 2013 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24101053